Biosig Technologies (BSGM)
(Delayed Data from OTC)
$0.32 USD
+0.01 (3.41%)
Updated Sep 18, 2024 03:48 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BSGM 0.32 +0.01(3.41%)
Will BSGM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BSGM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BSGM
The Cooper Companies (COO) Q3 Earnings Match Estimates
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
BSGM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
Hologic (HOLX) Tops Q3 Earnings and Revenue Estimates
Other News for BSGM
Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug
BSGM Stock Earnings: BioSig Technologies Misses EPS for Q2 2024
BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation
BioSig Technologies announces intent to acquire Nuero-Kinesis assets
BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024